UniCAR02-T, currently in a phase I trial for relapsed AML, ALL, and BPDCN, utilizes a unique approach where UniCAR T cells are activated by a specific recombinant antibody derivative targeting CD123 (TM123), which may enhance both specificity and safety [54] (Figure 3). The gene discussed is IL3RA; the disease is acute myeloid leukemia.